drugset
drugset / Trial / NCT03962647

A 2-Week Ketogenic Diet in Combination With Letrozole to Modulate PI3K Signaling in ER+ Breast Cancer

NCT03962647 ↗

Phase 0 Completed 31 enrolled Vanderbilt-Ingram Cancer Center
RandomizedSingle-groupOpen-labelTreatment

Summary

This is a neoadjuvant study to determine the feasibility and tolerability of 2 weeks of a very low carbohydrate ketogenic diet in combination with letrozole for patients with early stage operable ER+disease.

Timeline

Start
2019-07-08
Primary completion
2024-03-07
Completion
2024-07-14

Drugs

EvaluationDrugModalityDoseRoute
Background Letrozole Other / unclassified 2.5 mg Oral

Indications

estrogen-receptor positive breast cancer